The Mysteries and Underdiagnosis of SIBO
In 2017, shortly after she turned 32, Phoebe Lapine had just spent the previous three years overhauling her health to make up for her ailing thyroid, the result of unchecked Hashimoto’s thyroiditis. She was following a gluten-free diet, drinking kombucha and taking prebiotics, and finally feeling her best when she noticed peculiar gut symptoms starting to rear their head: burping during meals, stomach discomfort, and a bloated belly that simply would not deflate. She turned to a functional doctor who quickly gave her a diagnosis: small intestinal bacterial overgrowth (SIBO), a gut condition not uncommon for hypothyro...
Source: TIME: Health - March 7, 2022 Category: Consumer Health News Authors: Meaghan Beatley Tags: Uncategorized Source Type: news

Rifaximin cost effective in hepatic encephalopathy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

Rifaximin May Prevent Hepatic Encephalopathy After TIPS Placement for Cirrhosis Rifaximin May Prevent Hepatic Encephalopathy After TIPS Placement for Cirrhosis
The antibiotic rifaximin given before and after transjugular intrahepatic portosystemic shunt (TIPS) placement helped prevent hepatic encephalopathy (HE) in a placebo-controlled trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 6, 2021 Category: Surgery Tags: Gastroenterology News Source Type: news

Rifaximin Prevents Overt Hepatic Encephalopathy After TIPS
MONDAY, Feb. 1, 2021 -- For patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement, rifaximin used before and after the procedure is associated with a reduced risk for overt hepatic encephalopathy (HE),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2021 Category: Pharmaceuticals Source Type: news

Bausch Health And Alfasigma Announce Resolution Of XIFAXAN(R) Intellectual Property Litigation
Salix Will Maintain Market Exclusivity for XIFAXAN® (rifaximin) 550 mg Tablets Until 20281 LAVAL, Quebec, May 6, 2020 -- (Healthcare Sales & Marketing Network) -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "... Biopharmaceuticals, Litigation, Licensing Bausch Health Companies, Salix Pharmaceuticals, Alfasigma , Sandoz (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 6, 2020 Category: Pharmaceuticals Source Type: news

Antibiotics before liver transplants lead to better results
A UCLA-led research team has  found that giving mice antibiotics for 10 days prior to a liver transplant leads to better liver function after the surgery.After concluding the experiment mice, the scientists discovered data from liver transplants performed between October 2013 and August 2015 at the Ronald Reagan UCLA Medical Center, revealing that the same phenomenon appears to hold true in humans. The statistics from human patients even demonstrated that the people who were in worse health prior to their surgeries but received pre-surgery antibiotics fared better after their transplants than the patients who were health...
Source: UCLA Newsroom: Health Sciences - July 23, 2019 Category: Universities & Medical Training Source Type: news

rifaximin (Xifaxan)
Title: rifaximin (Xifaxan)Category: MedicationsCreated: 2/11/2011 12:00:00 AMLast Editorial Review: 3/19/2019 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - March 19, 2019 Category: Nutrition Source Type: news

Diverticulitis
This review notes the mainstay role of oral antibiotics for outpatient management has been challenged; rifaximin and mesalamine have been proposed as possible agents to reduce recurrence but available data do not suggest a substantive benefit. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 31, 2018 Category: Consumer Health News Source Type: news

Rifaximin Chaser May Cut CDI Relapse
(MedPage Today) -- Pooled data from two RCTs suggested 50% drop in recurrence after standard antibiotics (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 28, 2018 Category: Gastroenterology Source Type: news

Rifaximin (Xifaxan) for Irritable Bowel Syndrome (IBS) Treatment
Title: Rifaximin (Xifaxan) for Irritable Bowel Syndrome (IBS) TreatmentCategory: Doctor's& Expert's views on SymptomsCreated: 1/18/2011 12:00:00 AMLast Editorial Review: 6/13/2018 2:55:08 PM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - June 13, 2018 Category: Nutrition Source Type: news

Cost of hepatic encephalopathy and its reduction with rifaximin
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2018 Category: Drugs & Pharmacology Source Type: news

Xifaxan (Rifaximin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 2, 2018 Category: Drugs & Pharmacology Source Type: news

Statement Regarding Xifaxan Intellectual Property Litigation
LAVAL, Quebec, May 17, 2017 -- (Healthcare Sales & Marketing Network) -- Salix Pharmaceuticals, Inc. and parent Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Actavis Laboratories, Inc., at Actavis' request,... Biopharmaceuticals, Litigation Valeant Pharmaceuticals, Actavis Laboratories, Xifaxan, rifaximin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 17, 2017 Category: Pharmaceuticals Source Type: news

Economics of Treating Hepatic Encephalopathy With Rifaximin-a Economics of Treating Hepatic Encephalopathy With Rifaximin-a
Rifaximin-alpha is effect in treating hepatic encephalopathy, but its cost is high. Might it still be cost-saving due to reduced hospital admissions and shorter stays?Liver International (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 22, 2016 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news

Allergan Announces Receipt Of FDA Acceptable For Filing Letter For Generic XIFAXAN(R) ANDA
DUBLIN, Feb. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), a leading global pharmaceutical company, today announced that the Company has received an Acceptable for Filing letter from the U.S. Food and Drug Administration (FDA) ... Biopharmaceuticals, Generics, Gastroenterology, FDAAllergan, Valeant Pharmaceuticals, IFAXAN, rifaximin, irritable bowel syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 29, 2016 Category: Pharmaceuticals Source Type: news